Who are Boostrix™-US formulation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AVA, Typhim Vi (Sanofi Pasteur MSD).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/boostrix-us-formulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Boostrix™-US formulation — Competitive Intelligence Brief

Boostrix™-US formulation (Boostrix™-US formulation) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated bacterial vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated bacterial vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Boostrix™-US formulation (Boostrix™-US formulation) — GlaxoSmithKline. Boostrix is a vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Boostrix™-US formulation TARGET	Boostrix™-US formulation	GlaxoSmithKline	marketed	Inactivated bacterial vaccine
AVA	AVA	Emergent BioSolutions	marketed	Inactivated bacterial vaccine	Bacillus anthracis protective antigen (PA) and lethal factor
Typhim Vi (Sanofi Pasteur MSD)	Typhim Vi (Sanofi Pasteur MSD)	Universitaire Ziekenhuizen KU Leuven	marketed	Inactivated bacterial vaccine	Salmonella typhi Vi polysaccharide antigen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated bacterial vaccine class)

Emergent BioSolutions · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Universitaire Ziekenhuizen KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Boostrix™-US formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/boostrix-us-formulation. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab